FGF23 and metabolic syndrome: In this context, our group, following the increasingly convincing concept that pro-inflammatory factors may play a key role in the genesis of CV events in CKD, described an association between fibroblast growth factor 23 (FGF23) and the pro-inflammatory factor monocyte chemoattractant protein 1 (MCP1) in causing dyslipidemia [8].